MedTrace Logo

Immune Repertoire of Ovarian HGSC

NCT03794115 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-01-04

No results posted yet for this study

Summary

In this preliminary study, peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma at several points: before any treatment, after the debulking surgery, and after all the proposed chemotherapy. The differential expression of the T/B lymphocyte receptors in these samples will be analyzed with the platinum-based treatment and survival outcomes of the patients. The primary objective is the expression rates of T/B lymphocyte receptors in different stages of checking points.

Conditions

  • Ovarian High Grade Serous Carcinoma
  • Immune Repertoire
  • T Lymphocyte Receptor
  • B Lymphocyte Receptor

Interventions

PROCEDURE

Treatment for ovarian cancer

The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2021-01-01
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03794115 on ClinicalTrials.gov